


# amfAR

MAKING AIDS HISTORY



# 2018

# Annual Report

amfAR, The Foundation for AIDS Research



# Contents

<b>Dr. Mathilde Krim, AIDS Research Pioneer and Human Rights Leader, 1926-2018</b>	01
<b>amfAR in 2018</b>	03
<b>Grants, Fellowships, and Awards</b>	09
Research Grants, Fellowships, and Awards	
TREAT Asia Grants and Awards	
Public Policy Awards	
<b>Financial Highlights</b>	13
<b>Leadership and Advisory Committees</b>	15
Board of Trustees	
Scientific Advisory Committee	
Program Advisory Council	
Management Group	

**Our Mission: amfAR, The Foundation for AIDS Research, is dedicated to ending the global AIDS epidemic through innovative research.**



Photo: Annie Leibovitz

# Dr. Mathilde Krim

## AIDS Research Pioneer and Human Rights Leader 1926–2018

amfAR's revered Founding Chairman Mathilde Krim, Ph.D., died at her home on Long Island on January 15, 2018. She was 91.

Dr. Krim was at the forefront of philanthropic and scientific responses to HIV/AIDS long before the world fully understood its catastrophic global reach. In April 1983, along with Dr. Joseph Sonnabend and a small group of associates, Dr. Krim founded the AIDS Medical Foundation (AMF), the first private organization concerned with fostering and supporting AIDS research.

In 1985, AMF merged with a like-minded group based in California to form the American Foundation for AIDS Research (amfAR), which soon became the preeminent national nonprofit organization devoted to mobilizing the public's generosity in support of trailblazing laboratory and clinical AIDS research, HIV prevention, and advocacy.

"Dr. Krim had such a profound impact on the lives of so many," said amfAR Chief Executive Officer Kevin Robert Frost. "While we all feel a penetrating sadness at the loss of someone we loved so deeply, it is important to remember how much she gave us and the millions for whom she dedicated her life. There is joy to be found in knowing that so many people alive today literally owe their lives to this great woman."

**"AIDS has taught us a lesson that we should have learned long ago, namely that there is a high price to be paid whenever prejudice prevails over human solidarity."**

— Mathilde Krim, Ph.D.






## RESEARCH

### Countdown to a Cure for AIDS

In 2015, amfAR launched a multiyear \$100 million investment strategy to support its Countdown to a Cure for AIDS initiative, which is aimed at developing the scientific basis for a cure by the end of 2020. To date, amfAR has awarded 73 Countdown grants totaling more than \$47 million to support research conducted by more than 270 scientists working at 92 institutions in 16 countries. Structured to provide sustained support for a wide range of studies that advance both emerging and established ideas, the strategy comprises the following components:

- **The amfAR Institute for HIV Cure Research** was established in 2015 with a \$20 million grant over five years to the University of California, San Francisco. Researchers at the Institute have been laying the groundwork for a complex clinical study employing a three-pronged approach to eradicating HIV. A therapeutic vaccine will be combined with an immune adjuvant—a drug often used to boost the efficacy of vaccines—that has been



Dr. Weiming Yang

shown in clinical trials to have additional anti-HIV effects. The third component combines two broadly neutralizing antibodies, the source of much optimism in the cure field for their ability not only to kill viruses that are produced by infected cells, but also to direct the immune system to kill the very cells producing those viruses.

- **Investment Grants**, awarded over a four-year period, are aimed at recruiting the experience and expertise of scientists from outside the field of HIV. Grantees may have expertise in fields such as cancer, neuroscience, or inflammatory disease that can directly inform efforts to cure HIV. In February 2018, amfAR announced a pair of Investment grants totaling nearly \$1 million to allow two collaborative teams of HIV researchers and bioengineers to continue amfAR-funded projects into a second phase.

In the first phase of their study, one pair of researchers—Drs. Hui Zhang and Weiming Yang of Johns Hopkins University in Baltimore—used mass spectrometry to identify molecules on the surface of cells that differentiate latent reservoirs from uninfected cells. In Phase II, they are determining whether these newly identified proteins are able to distinguish the reservoir in patient samples.

In Phase I of their project, the other pair—Drs. Kim Woodrow and Keith Jerome of the University of Washington in Seattle—formulated new drug combinations loaded onto nanoparticles targeting the latent HIV reservoir. The nanoparticles preferentially delivered latency reversing agents to CD4 T cells, which reawakened the reservoir. In phase II, the researchers are testing the loaded nanoparticles and measuring their effects on the reservoir in a preclinical study.

- **Impact Grants** of up to \$2 million each over four years support the in-depth development of concepts already underpinned by preliminary data showing genuine potential for achieving a cure.

In September 2018, amfAR awarded grants totaling \$828,000 to advance two critical areas of HIV cure research. Five grants support efforts to understand the mechanisms and predictors of post-treatment control, and three support researchers studying HIV-positive populations in low- and middle-income countries to look for differences in how the persistent viral reservoir forms and changes over time.

- **ARCHE, the amfAR Research Consortium on HIV Eradication**, supports collaborative teams of scientists in the U.S. and around the world working on a range of HIV cure strategies. In September 2018, amfAR awarded \$800,000 in new funding through ARCHE to six teams of researchers developing an ambitious gene therapy-based approach to curing HIV, launching a critical new phase of a study initiated in 2017.

In a three-pronged attack on the HIV reservoir, the researchers are employing broadly neutralizing antibodies, CAR stem cells—cells genetically reprogrammed to recognize and attack disease cells—and molecular scissors targeting the virus. The grant was supported in part by the Bill and Melinda Gates Foundation.

The investigators are Dr. Hildegard Büning of Hannover Medical School, Germany; Dr. Keith Jerome of the University of Washington, Seattle; Dr. Hans-Peter Kiem of Fred Hutchinson Cancer Research Center, Seattle; Dr. Scott Kitchen of UCLA; Dr. Yasuhiro Takeuchi of University College London; Dr. Drew Weissman of University of Pennsylvania in Philadelphia; and Dr. Richard Wyatt of The Scripps Research Institute in La Jolla, CA.


- **The Mathilde Krim Fellowships in Basic Biomedical Research** support bright young scientists advancing innovative solutions to HIV/AIDS. In October 2017, amfAR announced three new Krim Fellows: Dr. Daniela Monaco, at Emory University in Atlanta; Dr. Gabriel Ozorowski, at The Scripps Research Institute in San Diego; and Dr. Jonathan Richard, at the University of Montreal, Canada. Another Krim fellow, Dr. Yen-Ting Lai of the Vaccine Research Center/National Institutes of Health in Bethesda, MD, was announced in September 2018. Each fellow is awarded approximately \$150,000 over two years.

## Published Research

Research studies make the greatest impact on the HIV field and on the broader scientific community when they are published in scientific journals. In FY2018, a record 80 scientific publications resulted from amfAR-funded research.

## IciStem

Created and funded by amfAR through its Countdown to a Cure for AIDS initiative, IciStem is a consortium of European researchers that has been working to replicate the case of the “Berlin patient.” The researchers are following a cohort of patients with cancer and HIV who have received, or soon will receive, a stem cell transplant. (The “London patient,” reported in March 2019 by IciStem researcher Dr. Ravi Gupta, was the first of the group’s patients to go into HIV remission and possibly the second person to have been cured of HIV.)



Dr. Eileen Scully of Massachusetts General Hospital was awarded an amfAR grant along with Dr. Jonathan Karn of Case Western Reserve University to study sex differences in HIV.

In June, amfAR awarded a new round of funding through ARCHE (see above) to advance the crucial work of IciStem. The award of approximately \$1.5 million over two years enabled the researchers to embark on the next phase of their scientific journey. To determine whether any of the patients in the cohort had been cured, they would withdraw antiretroviral therapy to test for evidence of viral rebound, the recurrence of persistent and detectable virus, in a strategic analytical treatment interruption trial.

## Sex and the HIV Reservoir

A groundbreaking study published in 2018 revealed that the female hormone estrogen has a significant effect on the persistent HIV reservoir. It suggests that women may respond differently than men to some curative interventions that are currently under investigation or, perhaps, that an effective cure for women could differ from a cure for men.

The study concludes that further investigations into sex differences in latency reversal and HIV persistence “are mandatory to extend the benefits of the HIV cure effort to all men and women impacted by the global epidemic.” Published in the *Proceedings of the National Academy of Sciences*, the findings are the most recent outgrowth of a multi-year amfAR investigation into sex differences in HIV.

## HIV Cure Summit

In November 2017, amfAR held its fourth annual HIV Cure Summit at UCSF. Participants included director of the amfAR Institute Dr. Paul Volberding; Institute board members Drs. Steven Deeks, Warner Greene, Satish Pillai, Peter Hunt, and Nadia Roan; Dr. Judith Auerbach of UCSF; and amfAR Vice President and Director of Research Dr. Rowena Johnston. Treatment activists and amfAR Institute community advisory board members Lynda Dee, Jeff Taylor, Loren Jones and Rob Newells—as well as HIV cure research participants Clark Hawley and Luis Canales—also shared their perspectives. The summit was organized around three panel discussions, which focused on potentially curative agents and strategies that are currently being developed and tested, and the relative merits of cure, i.e., total eradication of the virus, versus post-treatment control.



## PUBLIC POLICY

Informed by thorough research and analysis, amfAR is a highly respected advocate of rational and compassionate HIV/AIDS-related public policy. Through its Public Policy Office in Washington, DC, the Foundation advocates a wide range of policies to advance progress in combating and ending the HIV/AIDS epidemic in the U.S. and around the world.

amfAR advocates a strong commitment to HIV research and robust funding for the National Institutes of Health, as well as expanded access to affordable medicines for both HIV and hepatitis C (HCV). The policy office tracks budgetary decision-making in the U.S. and advocates for domestic, bilateral, and multilateral funding for HIV; and performs research on strategic and programmatic targets and progress reporting to ensure that programs are delivering services to all populations in need.

### The Global Epidemic and the Power of Data

amfAR is a leading advocate for continued robust U.S. support for the global HIV response through critical programs such as PEPFAR—the U.S. President’s Emergency Plan for AIDS Relief—and the Global Fund to Fight AIDS, Tuberculosis and Malaria.

In 2018, amfAR launched a new website—[mer.amfar.org](http://mer.amfar.org)—designed to support PEPFAR advocates by displaying data visualizations, maps, downloadable PDFs, district-level data, and implementing partner data, with descriptions of what each indicator means, how the results are measured, and how the data can be interpreted. The new website displays the full suite of programmatic data released by PEPFAR, including the targets and results for 30 monitoring and evaluation indicators.

The new data-driven site complements amfAR’s PEPFAR Country/Regional Operational Plans database—[copsdata.amfar.org](http://copsdata.amfar.org)—which contains budget and target information from publicly released documents that enable advocates to better understand who is being funded by PEPFAR in their countries. It highlights funding and targeted results by program area, country, and organization for each year.

amfAR funded a study with Johns Hopkins University, gay social network Hornet, MSM-GF, and Emory University to compare the number of gay and bisexual men using Hornet or Facebook in various countries to UNAIDS population size estimates. A resulting infographic shows that the study produced a much more accurate estimate (triple the official estimate) of the number of men who have sex with men (MSM) in Tanzania. More accurate estimates help PEPFAR and the Global Fund set HIV prevention targets and budgets sufficient for the needs of key populations.

### Funding and Policy Threats

In March 2018, amfAR published an infographic showing that the Trump Administration’s proposed FY2019 budget—including a 17% cut (of \$800 million) in funding for PEPFAR—could disrupt the supply of lifesaving antiretroviral therapy to more than a million adults living with HIV, and lead to close to 100,000 new HIV infections and hundreds of thousands of preventable AIDS-related deaths.

In July, amfAR Vice President and Director of Public Policy Greg Millett coauthored a *Lancet* report warning that UNAIDS targets to end the HIV epidemic by 2030 can only be met with stronger combined health service integration and by incorporating HIV into global health policy. This report on the “dangerous complacency” threatening the global HIV response coincided with a UNAIDS report warning of new HIV infections increasing in some 50 countries, AIDS-related deaths not falling fast enough, and insufficient resources to sustain progress.

Also in July, amfAR published an updated issue brief outlining serious potential impacts on global AIDS funding of the Mexico City Policy, which has historically prohibited U.S. family planning funding for non-U.S. nongovernmental organizations performing or promoting abortion. The policy was revived and expanded by the Trump Administration in January 2017.



### HIV and the Opioid Epidemic

amfAR is committed to reducing the risk of acquiring HIV and hepatitis C through the sharing of contaminated needles/syringes and advocating for harm reduction policies to improve outcomes for people who inject drugs.

The policy office maintains an interactive online database of epidemiological, policy, and funding data on opioid use, HIV, and hepatitis C. Maps from this highly effective advocacy tool have appeared in *The New York Times* and have been used in Congressional briefings and meetings, and at the National Academy of Sciences, as well as in local news broadcasts.

In January 2018, amfAR published an analysis in *Health Affairs* detailing the national availability of medication-assisted treatment (MAT) for opioid use disorder, specifically where drug treatment facilities offer several of the three currently available drugs. The authors report that many areas heavily affected by the opioid epidemic have no facilities that provide all three forms of MAT and accept Medicaid.

A subsequent infographic showed that nearly 30% of Americans live more than 10 miles from a facility providing MAT and nearly 80% live more than 10 miles from a syringe services program. At the Conference on Retroviruses and Opportunistic Infections in Boston in March, an amfAR poster showed that while there has been some progress in increasing access to syringe services facilities in vulnerable counties, overall access remains low.



In April 2018, amfAR published the report *Toward an Effective Strategy to Combat HIV, Hepatitis C and the Opioid Epidemic: Recommendations for Policy Makers*, which proposes a multifaceted approach to increase access to treatment, reduce HIV and HCV acquisition, and lower the risk of fatal drug overdoses.

amfAR also published an analysis in the *American Journal of Public Health* assessing the impact of Medicaid expansion on the opioid epidemic. The study found that that Medicaid expansion increased access to addiction treatment, and was not associated with higher opioid prescription rates.

## Hepatitis C

Driven by rising rates of injection drug use, the incidence of hepatitis C (HCV) in the U.S. has tripled in the last five years. The amfAR policy office advocates for increased access to prevention and treatment services for people living with, or at risk for, HCV, and maintains a database of epidemiologic, policy, and funding data on opioid use, HIV, and HCV ([opioid.amfar.org](http://opioid.amfar.org)—see above).

## Ending the Domestic HIV Epidemic

In July 2018, amfAR published a series of reports to advance the difficult process of developing and deploying long-acting HIV treatment and prevention products currently in the pipeline. *Long-Acting HIV Treatment and Prevention Are Coming: Preparing for Potential Game Changers* describes the critical issues (e.g., FDA review and approval, payer coverage, and access decisions) that must be navigated by policy makers to make these new products available for people living with HIV or vulnerable to infection.



## TREAT ASIA

amfAR's TREAT Asia (Therapeutics Research, Education, and AIDS Training in Asia) program is a network of hospitals, clinics, and research institutions working with civil society to ensure the safe and effective delivery of treatments for HIV and its co-infections to adults and children across the Asia-Pacific through research, education,

and advocacy of evidence-based HIV-related policies. The TREAT Asia Network encompasses 21 adult and 20 pediatric sites throughout the region, which collaborate on a variety of projects. TREAT Asia scientists produced 20 publications in peer-reviewed medical journals in FY2018.


## Gathering Critical Information

TREAT Asia pioneered the region's first adult observational database for HIV/AIDS, which now includes anonymous data from nearly 10,000 patients at 21 clinical sites in 12 countries. The information gathered informs the development of more effective research and treatment programs and helps define treatment standards specific to HIV/AIDS in Asia. The TAHOD-LITE database, an extension of TAHOD, contains data from over 37,000 HIV-positive patients across 10 TREAT Asia network sites and aims to increase the scope of adult data collection by gathering a subset of core variables from all HIV-infected patients who have sought care at selected TAHOD sites.

## A Global Collaboration

Since 2006, TREAT Asia has managed the Asia-Pacific section of the International Epidemiology Databases to Evaluate AIDS (IeDEA), a global collaboration established by the U.S. National Institute of Allergy and Infectious Diseases. In FY2018 IeDEA funded many TREAT Asia studies, including (along with ViiV Healthcare) the third year of STAY (Study of Transitioning Asian Youth), which is documenting the experience of HIV-infected young adults who are transitioning from pediatric to adult care.

Since 2016 IeDEA and ViiV Healthcare have also funded the TREAT Asia Study to Evaluate Resistance 2 (TASER-2) to improve assessment of virologic failure and associated HIV drug resistance in HIV-infected adults on second-line ART. The study's goal is to better predict the need for third-line ART regimens in the region, as well as to facilitate advocacy efforts for inclusion of third-line options in national treatment guidelines and expansion of routine viral load testing capacities.



In FY2018 IeDEA also funded the second year of *GRADUATE: a Global fRamework of Data collection Used for Adolescent HIV Transition Evaluation*, which aims to improve how clinical and program data on adolescents living with HIV are organized and studied in resource-limited settings. Led by amfAR Vice President and TREAT Asia Director Dr. Annette Sohn and Dr. Mary-Ann Davies of the University of Cape Town, South Africa, GRADUATE is being conducted in Malawi, South Africa, and Thailand.

As part of TREAT Asia’s initiative to address the mental health concerns of adolescents living with HIV in Asia, an IeDEA-funded study begun in early 2018 is evaluating the prevalence and clinical course of depression and anxiety in Thai adolescents with HIV. Dr. Tavitiya Sudjaritruk of Chiang Mai University, Thailand, is leading the study.

## Improving Care for Children

The TREAT Asia Pediatric HIV Observational Database (TApHOD) is a regional pediatric HIV study begun in 2006. It was modeled after the adult database and includes data from more than 6,400 children and adolescents at 18 clinical sites in Cambodia, India, Indonesia, Malaysia, Thailand, and Vietnam.


## Empowering Youth Advocates

The second class of TREAT Asia’s Youth ACATA—Asia Community for AIDS Treatment and Advocacy—continued its two-year leadership training program in FY2018. With support from ViiV Healthcare’s Positive Action for Adolescents program, Youth ACATA has educated participants about HIV and antiretroviral therapy and connected them to other HIV-positive youth in the region. Its members have participated in global youth programs, including SPARK17 and the International AIDS Society’s Adolescent Treatment Coalition.

## Helping Adolescents Transition to Adult Care

In January 2018, in collaboration with young people living with HIV, social workers, and pediatricians in the Asia-Pacific region, TREAT Asia developed tools to help providers manage the transition of adolescents from pediatric to adult HIV clinics. They include a flipchart, available in English and five regional languages, for use during provider-patient discussions. Production was supported by the Thai Red Cross AIDS Research Centre and ViiV Healthcare.

A presentation on these tools was included in trainings that TREAT Asia and regional partners conducted in Cambodia, Indonesia, Malaysia, Thailand, and Vietnam for clinicians who work with HIV-positive children and adolescents, to help them better prepare their patients for the move to adult care.



## Addressing Adult Mental Health

In January 2018, TREAT Asia organized a think tank in Bangkok on mental health concerns in adults living with HIV in Asia. Like children and adolescents, adults living with HIV have a higher prevalence of anxiety and depression compared with their uninfected peers,

and these issues have been inadequately studied and treated. The think tank brought together researchers, clinicians, and psychologists from across Asia and from Columbia University in New York City, who considered research, policy, and capacity development activities that might help address gaps in mental health management in HIV care settings in the region.

## Advocating for HIV and Co-Infection Treatment Access

In October 2017, amfAR’s Public Policy Office and TREAT Asia organized a consultation in Bangkok with experts from local, national, regional, and international organizations in Asia, Europe, Africa, and North America to draft “essential standards” for voluntary licenses—arrangements whereby a patent holder allows others to manufacture, import, and/or distribute its patented drug.

In the same month, TREAT Asia and the international association Coalition PLUS began a partnership to improve hepatitis C diagnosis and treatment access in Asia through the Unitaid-funded “HIV/HCV drug affordability project.” The partnership’s goal is to build local movements towards implementing national treatment programs by engaging with local civil society organizations and policy makers.

In November and December 2017, TREAT Asia organized two trainings on hepatitis B and C and the importance of addressing these diseases in the context of HIV co-infection. The trainings, for community members, treatment advocates, and clinicians, focused on the World Health Organization (WHO) hepatitis B and C screening and treatment guidelines and on implementing them at the national level.

In collaboration with the WHO South East Asia and Western Pacific Regional Offices, TREAT Asia organized a roundtable discussion in Bangkok in September 2018 titled “Enhancing access to newer HIV and hepatitis C medicines.” Managers from intellectual property offices, national regulatory bodies, and HIV programs in nine Asian countries attended, along with representatives from the Clinton Health Access Initiative, Medicines Patent Pool, Drugs for Neglected Diseases initiative, and UNAIDS.

In June 2018, TREAT Asia produced a policy brief titled *Hepatitis C: Policy Recommendations for Addressing a Growing Epidemic*. The brief spells out specific steps that national governments should take to improve access to care and treatment.

## Providing PrEP in the Philippines

In FY2018, Project PrEPY, a two-year pilot project being conducted in Manila, the Philippines, completed enrollment and began evaluating community-based, peer-driven delivery of antiretroviral pre-exposure prophylaxis (PrEP). Project PrEPY aims to curb the rapid spread of HIV among MSM and transgender individuals in the Philippines. amfAR is among several organizations involved in the study, a multiagency collaboration with experts from government, academia, and multilateral and nongovernmental organizations. Based on results from the first year of the project, the Philippines is expanding PrEP services to other parts of the country.

## PUBLIC INFORMATION

amfAR disseminates information on important HIV-related research, treatment, prevention, and policy issues for diverse audiences to increase awareness and knowledge of the pandemic. amfAR publishes a wide range of educational materials and engages respected public figures, HIV/AIDS scientists, and policymakers in communicating the need for continued research to develop new methods of prevention, treatment, and, ultimately, a cure for HIV.

### Educational Materials

amfAR produces periodicals in both print and electronic formats, including its newsletter *Innovations*, published twice a year and distributed to about 40,000 people; the *TREAT Asia Report*, an email newsletter distributed six times a year to more than 4,000 readers in the international health community; and a monthly e-mail newsletter distributed to nearly 70,000 people. The Foundation's websites—[www.amfAR.org](http://www.amfAR.org) and [www.curecountdown.org](http://www.curecountdown.org)—feature news, interviews, and original articles covering HIV research, policy, the global epidemic, and amfAR programs and activities. The websites attract a combined average of 45,000 visitors per month.

amfAR also creates and distributes reports, press releases, and updates on major HIV/AIDS issues and conducts public service advertising campaigns that have been instrumental in educating policymakers, healthcare professionals, people living with HIV/AIDS, and the public.

### Epic Voices

In FY2018, amfAR added eight new *Epic Voices* to the original four posted on [curecountdown.org](http://curecountdown.org). Launched in 2017, *Epic Voices* is an online video series aimed at reenergizing the response to HIV among millennial and LGBTQ communities. The goals of the campaign are to renew awareness of the persistent threat of HIV, underscore the urgent need to advance HIV research, and support amfAR's leadership in the search for a cure. Along with activists and people living with HIV, the campaign features leading researchers and public health professionals.

## Social Media

amfAR has vigorously expanded its presence in the social media arena, reaching large numbers of people, including a younger demographic that is often less educated about HIV. The Foundation regularly adds content to its Facebook page, live tweets from events, and posts images on Instagram from fundraising and programmatic events. amfAR has 73,000 likes on Facebook, 43,000 Twitter followers, and more than 155,000 Instagram followers.

## Media Outreach

In FY2018, amfAR continued to work closely with the media to raise the profile of HIV/AIDS, both domestically and internationally, and to help ensure the accuracy of HIV-related press coverage. Articles and reports involving amfAR—many of which included interviews with staff—were carried in numerous media outlets, including *The Lancet*, *The New York Times*, *The Washington Post*, the *Chicago Tribune*, the Associated Press, *NPR*, *U.S. News & World Report*, *TIME*, *The Hill*, *CNBC*, *CNN*, *CBS News*, *NBC News*, *Politico*, *BuzzFeed*, *Vox*, *Kaiser Health News*, *Harper's Bazaar*, *Vogue*, and *HuffPost*.

## Celebrity Support

amfAR's public awareness efforts are greatly enhanced by the committed support of public figures who lend their voices and donate their time, talents, and resources to help sustain the Foundation's mission. Support of amfAR by prominent public figures began with the late Dame Elizabeth Taylor, amfAR's Founding International Chairman, and others have followed in her footsteps.

Heidi Klum was featured in amfAR's public service awareness campaign about safe sex, which garnered significant media coverage. Other celebrity supporters included amfAR Ambassadors Milla Jovovich and Michelle Yeoh, Edward Enninful, Angela Missoni, Dean and Dan Caten, Kate Hudson, Donatella Versace, Katy Perry, Sienna Miller, Karolina Kurkova, Grace Jones, Ellie Goulding, Jason Derulo, Neymar Jr., Pierce Brosnan, Jean-Paul Gaultier, Kate Moss, Lee Daniels, Stefano Tonchi, Halsey, Taraji P. Henson, Alan Cumming, Whoopi Goldberg, Iman, Scarlett Johansson, Queen Latifah, Laura Linney, Julia Roberts, Tom Hanks, James Corden, Fergie, Charlize Theron, Adrien Brody, Jessica Chastain, Matt Bomer, Gwyneth Paltrow, Diana Ross, Katie Holmes, Uma Thurman, Zoe Saldana, Lea Michele, Michelle Rodriguez, Naomi Campbell, Jon Hamm, Eva Longoria, Chris Tucker, Jennifer Garner, Victoria Justice, and Carine Roitfeld.





## 2018 RESEARCH GRANTS, FELLOWSHIPS AND AWARDS

All projects listed below were awarded funding during the period October 1, 2017, through September 30, 2018.

### amfAR RESEARCH CONSORTIUM ON HIV ERADICATION (ARCHE)

[Allogeneic stem cell transplant in HIV-1-infected individuals \(third renewal\)](#)

Annemarie Wensing, MD, PhD  
University Medical Center Utrecht, Utrecht, The Netherlands  
Javier Martínez-Picado, PhD  
AIDS Research Institute, IrsiCaixa, Barcelona, Spain  
\$1,560,000

### INVESTMENT GRANTS: BRINGING BIOENGINEERS TO CURE HIV—PHASE II

[Targeted nanocarriers to accelerate depletion of the HIV reservoir](#)

Keith Jerome, MD, PhD  
University of Washington  
Seattle, WA  
\$500,000

[Deciphering latency-associated sugar code to detect and eliminate latent reservoir](#)

Weiming Yang, PhD  
Johns Hopkins University  
Baltimore, MD  
\$499,114

### MATHILDE KRIM FELLOWSHIPS IN BASIC BIOMEDICAL RESEARCH

[Impact of pre-adaptation on viral evolution and virus control in the newly infected individual](#)

Daniela Monaco, PhD  
Emory University  
Atlanta, GA  
\$150,000

[Exploiting dynamic conformational states of HIV-1 Env as targets for novel inhibitors](#)

Gabriel Ozorowski, PhD  
The Scripps Research Institute  
La Jolla, CA  
\$150,000

[Harnessing NK cell responses to eliminate HIV-1-infected cells](#)

Jonathan Richard, PhD  
Université de Montréal, Centre de Recherche du CHUM  
Montreal, Canada  
\$150,000

### MATHILDE KRIM FELLOWSHIP GRANTS—PHASE II

[Identifying genetic determinants of latency establishment and maintenance](#)

Judd Hultquist, PhD  
Northwestern University  
Chicago, IL  
\$76,416

[A3G-induced virus evolution](#)

Spyridon Stavrou, PhD  
State University of New York at Buffalo  
Amherst, NY  
\$50,000


[Vaccines through the eyes of B cells](#)

Marit van Gils, PhD  
Academic Medical Center of the University of Amsterdam  
Amsterdam, The Netherlands  
\$80,000

### MEETINGS AND CONFERENCES

[Advanced Course on HIV Pathogenesis, XIII Edition](#)

Esper Kallás, MD, PhD  
Fundação Faculdade de Medicina  
São Paulo, Brazil  
\$15,000





## 2018 TREAT ASIA GRANTS AND AWARDS

All projects listed below were awarded funding during the period October 1, 2017, through September 30, 2018.

<sup>1</sup>Supported by National Institutes of Health cooperative agreement number U01AI069907 with funds from the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Cancer Institute, the National Institute of Mental Health, and the National Institute on Drug Abuse

<sup>2</sup>Supported by National Institutes of Health grant number R01HD073972 funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development

<sup>3</sup>Supported with funds provided by Viiv Health Care

<sup>4</sup>Supported with funds provided by the Open Society Foundations

### AUSTRALIA

#### University of New South Wales

Sydney  
Matthew G. Law, PhD  
IeDEA Asia-Pacific Research Collaboration:  
TREAT Asia HIV Observational Database &  
Australia HIV Observational Database  
\$275,346<sup>1</sup>

IeDEA Asia-Pacific Research Collaboration:  
TREAT Asia Pediatric HIV Observational Database  
\$211,224<sup>1</sup>

IeDEA Asia-Pacific Research Collaboration:  
Cancer Studies  
\$95,982<sup>1</sup>

### AUSTRALIAN HIV RESEARCH COLLABORATION (AHOD) SITES

#### O'Brien Street Practice

Adelaide  
William Donohue, MBBS  
\$1,800

#### Sexual Health and HIV Service In Metro North

Brisbane  
Diane Rowling, MBBS, MTH, F(PHM), RACP, FACSMM  
\$5,775

#### Cairns Sexual Health Service

Cairns  
Darren Russell, MD  
\$7,500<sup>1</sup>

#### RPA Sexual Health Clinic

Camperdown  
David Templeton, PhD  
\$7,350<sup>1</sup>

#### Melbourne Sexual Health Centre

Carlton  
Tim Read, MBBS, DipVen, FRACGP, FACHSHM, EpiDip  
\$6,150<sup>1</sup>

#### Monash Health - Clayton

Clayton  
Ian Woolley, MBBS, FRACP  
\$7,500

#### D.A. Ellis Pty Ltd

Coffs Harbour  
David Ellis, MBBS  
\$525

#### East Sydney Doctors

Darlinghurst  
David Baker, MB, ChB, Dip Med (Sexual Health), DCH  
\$6,225<sup>1</sup>

#### St. Vincent's Hospital Sydney Limited

Darlinghurst  
David A. Cooper, MD  
\$7,500<sup>1</sup>

#### Taylor Square Private Clinic

Darlinghurst  
Robert Finlayson, MBBS (Syd), Di  
\$6,975<sup>1</sup>

#### Northern Territory Dept of Health & Community Services, Sexual Health & Blood Borne Virus Program

Darwin  
Manoji Gunathilake, MBBS, MD, FACHSHM  
\$2,025

#### Gladstone Road Medical Centre

Highgate Hill  
David Orth, MBBS, DIP Ven  
\$6,225<sup>1</sup>

#### Nepean Blue Mountains Local Health District, Blue Mountains Sexual Health and HIV Clinic

Katoomba  
Eva Jackson, MBBS, FACHSHM  
\$2,175

#### Nepean Blue Mountains Local Health District, Nepean Sexual Health Clinic

Kingswood  
Eva Jackson, MBBS, FACHSHM  
\$1,950

#### Sexual Health and AIDS Services (SHAIDS)

Lismore  
David Smith, MBBS, DipVen, FACHSHM, GrapDip, BA  
\$7,425<sup>1</sup>

#### Victorian HIV Service, Infectious Diseases Department, The Alfred Hospital

Melbourne  
Jennifer Hoy, MBBS  
\$7,500<sup>1</sup>

#### Sunshine Coast Hospital and Health Service

Nambour West  
David Sowden, MBBS  
\$7,500<sup>1</sup>

#### Northside Clinic (Vic) Pty Ltd

North Fitzroy  
Richard Moore, MBBS  
\$7,500<sup>1</sup>

#### Royal Perth Hospital

Perth  
David Nolan, MBBS, FRACP, PhD  
\$6,450<sup>1</sup>

#### Prahran Market Clinic Pty Ltd

Prahran  
Norman Roth, MBBS, FACHSHM  
\$7,500<sup>1</sup>

#### Holdsworth House Medical Practice

Sydney  
Mark Bloch, MD  
\$7,500<sup>1</sup>

#### Sydney Sexual Health Centre, Sydney Hospital

Sydney  
Rick Varma, MBBS, MRCP  
\$6,600<sup>1</sup>

#### Clinic 468, HNE Sexual Health, Hunter New England Local Health District

Tamworth  
Nathan Ryder, MD  
\$1,650

#### Illawarra Shoalhaven Local Health District

Warrarong  
Katherine Brown, MD  
\$1,875

### CAMBODIA

#### National Center for HIV/AIDS, Dermatology & STDS / Cambodia National Institute of Public Health

Phnom Penh  
Ly Penh Sun, MD, MSc  
TREAT Asia HIV Observational Database (TAHOD)  
\$20,800<sup>1</sup>

TREAT Asia Pediatric HIV Observational Database (TApHOD) Site  
\$25,000

### CHINA

#### Beijing Ditan Hospital

Beijing  
Fujie Zhang, MD, MSPH, PhD  
TREAT Asia HIV Observational Database (TAHOD)  
\$19,760<sup>1</sup>

#### Queen Elizabeth Hospital

Hong Kong  
Man Po Lee, MBBS  
TREAT Asia HIV Observational Database (TAHOD) including NCD Data  
\$23,920<sup>1</sup>

### INDIA

#### B.J. Government Medical College

Pune  
Aarti Kinikar, MD, DCH; DNB; MRCP Pediatrics UK  
TREAT Asia Pediatric HIV Observational Database (TApHOD) Site  
\$20,000<sup>1</sup>

#### Shashikala Sangle, MD

TREAT Asia HIV Observational Database (TAHOD) including NCD Data  
\$23,712<sup>1</sup>

#### Institute of Infectious Diseases

Pune  
Sanjay Pujari, MD, AAHIVS, MBBS  
TREAT Asia HIV Observational Database (TAHOD) including NCD Data  
\$23,296<sup>1</sup>

Wide Angle Social Development Organization  
Imphal  
Rajkumar Nalinikanta  
Improving HBV & HCV prevention & treatment  
access in Manipur—Phase V  
\$8,704<sup>4</sup>

## INDONESIA

Sanglah Hospital, Udayana University School of  
Medicine  
Denpasar  
Tuti Parwati Merati, MD, PhD  
TREAT Asia HIV Observational Database (TAHOD)  
including NCD Data  
\$23,296<sup>1</sup>

Ketut Dewi Kumara Wati, MD  
TREAT Asia Pediatric HIV Observational Database  
(TApHOD) Site  
\$7,500

Cipto Mangunkusumo General Hospital  
Jakarta  
Nia Kurniati, MD  
TREAT Asia Pediatric HIV Observational Database  
(TApHOD) Site  
\$7,500<sup>1</sup>

Evy Yuniastuti, MD, PhD  
TREAT Asia HIV Observational Database (TAHOD)  
including NCD Data  
\$23,712<sup>1</sup>

## JAPAN

National Center for Global Health and Medicine  
Shinjuku  
Junko Tanuma, MD, PhD  
TREAT Asia HIV Observational Database (TAHOD)  
\$16,640<sup>1</sup>

## MALAYSIA

Penang Hospital  
Georgetown  
Revathy Nallusamy, MBBS  
TREAT Asia Pediatric HIV Observational Database  
(TApHOD) Site  
\$2,500

Hospital Raja Perempuan Zainab II  
Kota Bharu  
Nik Khairulddin Nik Yusoff, MD  
TREAT Asia Pediatric HIV Observational Database  
(TApHOD) Site  
\$7,500

Hospital Likas  
Kota Kinabalu  
Fong Siew Moy, MBBS  
TREAT Asia Pediatric HIV Observational Database  
(TApHOD) Site  
\$7,500

Pediatric Institute, Hospital Kuala Lumpur  
Kuala Lumpur  
Thahira Mohamed, MBBS  
TREAT Asia Pediatric HIV Observational Database  
(TApHOD) Site  
\$7,500

University of Malaya  
Kuala Lumpur  
Adeeba Kamarulzaman, MBBS, FRACP, FAMM,  
FASC  
TREAT Asia HIV Observational Database (TAHOD)  
including NCD Data  
\$23,608<sup>1</sup>

Sungai Buloh Hospital  
Sungai Buloh  
Yasmin Mohamed Gani, MD  
Study of Transitioning Asian Youth (STAY) Cohort  
Study Site  
\$7,967<sup>3</sup>

Benedict Lim Heng Sim, MBBS, MRCP  
TREAT Asia HIV Observational Database (TAHOD)  
including NCD Data  
\$17,368<sup>1</sup>

## PHILIPPINES

Asian Foundation for Tropical Medicine, Inc.  
Muntinlupa City  
Rossana Ditangco, MD  
TREAT Asia HIV Observational Database (TAHOD)  
including NCD Data  
\$22,800 (year 12); \$23,608 (year 13)

## SINGAPORE

Tan Tock Seng Hospital  
Singapore  
Oon Tek Ng, MBBS, MRCP, MMed, MPH  
TREAT Asia HIV Observational Database (TAHOD)  
\$18,720<sup>1</sup>

## SOUTH KOREA

Yonsei University College of Medicine  
Seoul  
Jun Yong Choi, MD, PhD  
TREAT Asia HIV Observational Database (TAHOD)  
including NCD Data  
\$18,928<sup>1</sup>

## TAIWAN

Taipei Veterans General Hospital  
Taipei City  
Wing-Wai Wong, MD; Yu-Jiun Chan, MD, PhD  
TREAT Asia HIV Observational Database (TAHOD)  
including NCD Data  
\$27,040<sup>1</sup>; \$2,004 (supplement)

## THAILAND

Chulalongkorn University  
Bangkok  
Thanyawee Puthanakit, MD  
TREAT Asia Pediatric HIV Observational Database  
(TApHOD) Site  
\$15,000<sup>1</sup>

Prevalence and clinical course of mental health  
disorders among HIV-infected Thai adolescents  
\$8,310<sup>1</sup> (year 1); \$8,457<sup>1</sup> (year 2)

HIV-NAT / Thai Red Cross AIDS Research Centre  
Bangkok  
Anchalee Avihingsanon, MD, PhD  
TREAT Asia HIV Observational Database (TAHOD)  
including NCD Data  
\$24,960<sup>1</sup>; \$612 (supplement)

Sivaporn Gatechompol, MD  
Study Site: Human Papillomavirus Infection in  
Perinatally HIV-infected Adolescents in Asia  
\$4,763<sup>2</sup>; \$22,902<sup>2</sup> (supplement)

Nittaya Phanuphak, MD, PhD  
Human Papillomavirus Infection in Perinatally  
HIV-infected Adolescents in Asia (central lab &  
data manager) Supplement  
\$65,027<sup>2</sup>; \$194,062<sup>2</sup> (supplement)

Thai Red Cross AIDS Research Centre  
Bangkok  
Nittaya Phanuphak, MD, PhD  
Anal HPV and risk for anal high-grade squamous  
intraepithelial lesion among Thai MSM with acute  
HIV infection  
\$93,785<sup>1</sup>

Mahidol University by Faculty of Medicine Siriraj  
Hospital  
Bangkok  
Kulkanya Chokephaibulkit, MD  
TREAT Asia Pediatric HIV Observational Database  
(TApHOD) Site  
\$7,500<sup>1</sup>

Human Papillomavirus Infection in Perinatally HIV-  
infected Adolescents in Asia Supplement  
\$9,242<sup>2</sup>; \$22,918<sup>2</sup> (supplement)

Study of Transitioning Asian Youth (STAY) Cohort  
Study Site  
\$13,381<sup>1</sup>

Ramathibodi Hospital, Mahidol University  
Bangkok  
Sasisopin Kiertiburanakul, MD, MHS  
TREAT Asia HIV Observational Database (TAHOD)  
including NCD Data  
\$24,024<sup>1</sup>

Chiang Mai University - Research Institute for  
Health Sciences  
Chiang Mai  
Romanechaiwarith, MD, MHS  
TREAT Asia HIV Observational Database (TAHOD)  
including NCD Data  
\$24,856<sup>1</sup>

Tavitiya Sudjaritruk, MD, ScM  
TREAT Asia Pediatric HIV Observational Database  
(TApHOD) Site  
\$15,000<sup>1</sup>

Prevalence and clinical course of mental health  
disorders among HIV-infected Thai adolescents  
\$20,263<sup>1</sup> (year 1); \$20,357<sup>1</sup> (year 2)

Peripheral Arterial Diseases among Perinatally HIV-  
infected Thai Adolescents (PAD study) Supplement  
\$725

Chiangrai Prachanukroh Hospital  
Chiang Rai  
TREAT Asia Pediatric HIV Observational Database  
(TApHOD) Site  
\$15,000<sup>1</sup>

Study of Transitioning Asian Youth (STAY) Cohort  
Study Site  
\$11,878<sup>3</sup>

Suwimon Khusuwan  
TREAT Asia HIV Observational Database (TAHOD)  
including NCD Data  
\$23,400<sup>1</sup>

Srinagarind Hospital, Khon Kaen University  
Khon Kaen  
Pagakrong Lumbiganon, MD  
TREAT Asia Pediatric HIV Observational Database  
(TApHOD) Site  
\$7,500

Study of Transitioning Asian Youth (STAY) Cohort  
Study Site  
\$11,878<sup>3</sup>

#### Purple Haze Company Limited

Muang  
Tarandeep Anand  
The impact of online interventions on the HIV  
prevention/treatment cascade among MSM  
and TG individuals  
\$32,100<sup>1</sup>

## USA

#### Johns Hopkins University

Baltimore, CA  
Vidya Mave, MD, MPH  
Epidemiology of HIV/AIDS and associated  
comorbidities in a public antiretroviral treatment  
(ART) clinic in Pune, India  
\$212,982<sup>1</sup>

#### Super Models for Global Health

Berkeley, CA  
James Kahn, MD, MPH  
CVD screening and management practices among  
HIV clinics in Asia—leDEA  
\$20,000<sup>1</sup>

## VIETNAM

#### Bach Mai Hospital

Hanoi  
Do Duy Cuong, MD, PhD  
TREAT Asia HIV Observational Database (TAHOD)  
including NCD Data  
\$23,504<sup>1</sup>

#### National Hospital of Pediatrics

Hanoi  
Nguyen Van Lam, MD, MSc  
TREAT Asia Pediatric HIV Observational Database  
(TApHOD) Site  
\$20,000<sup>1</sup>

Study of Transitioning Asian Youth (STAY) Cohort  
Study Site  
\$9,039<sup>3</sup>

Nguyen Van Kinh, MD, PhD  
TREAT Asia HIV Observational Database (TAHOD)  
including NCD Data  
\$23,504<sup>1</sup>

#### Children's Hospital 1

Ho Chi Minh City  
Truong Huu Khanh, MD  
TREAT Asia Pediatric HIV Observational Database  
(TApHOD) Site  
\$25,000<sup>1</sup>

#### Children's Hospital 2

Ho Chi Minh City  
Do Chau Viet, MD  
TREAT Asia Pediatric HIV Observational Database  
(TApHOD) Site  
\$20,000

## 2018 PUBLIC POLICY AWARDS

The project listed below was awarded  
amfAR funding during the period October 1,  
2017, through September 30, 2018.

\*Funded with support from the Ford Foundation

#### Increasing access to services for PLHIV who use drugs in the Philippines

Project Director: Cara O'Connor  
Sustained Health Initiatives of the Philippines  
Mandaluyong City, Philippines  
\$24,989



## Financial Highlights

For the year ended September 30, 2018




<b>Public Support and Revenue</b>		
Public support	\$	4,331,124
Special events		19,098,255
Planned giving		1,559,284
Government funding		5,761,067
Investment income and other revenue		1,221,687
<b>Total public support and revenue</b>	<b>\$</b>	<b>31,971,417</b>
<hr/>		
<b>Expenses</b>		
Research	\$	18,293,927
TREAT Asia		5,051,148
GMT Initiative		921,895
Public Policy		2,140,923
Public Information		4,141,818
<b>Total program services</b>	<b>\$</b>	<b>30,549,711</b>
<hr/>		
Fundraising		6,014,275
Management and general		2,586,998
<b>Total supporting services</b>	<b>\$</b>	<b>8,601,273</b>
<hr/>		
<b>Total expenses</b>	<b>\$</b>	<b>39,150,984</b>
<hr/>		
Change in net assets		(7,179,567)
Net assets, beginning of year		59,730,246
<b>Net assets, end of year</b>	<b>\$</b>	<b>52,550,679</b>


## Statement of Financial Position

<b>Assets</b>		
Cash and investments	\$	55,041,086
Pledges and receivables, net		7,088,076
Prepaid expenses and other assets		4,485,440
Furniture, equipment, and leasehold improvements, net		2,921,534
<b>Total Assets</b>	<b>\$</b>	<b>69,536,136</b>
<hr/>		
<b>Liabilities</b>		
Accounts payable and accrued expenses	\$	3,655,122
Grants and fellowships payable, net		2,768,840
Deferred support and refundable advances		8,596,427
Other long-term liabilities		1,965,068
<b>Total liabilities</b>	<b>\$</b>	<b>16,985,457</b>
<hr/>		
<b>Total net assets</b>		<b>52,550,679</b>
<hr/>		
<b>Total liabilities and net assets</b>	<b>\$</b>	<b>69,536,136</b>









## Expenses

	Fundraising	\$	6,014,275
	Management and general		2,586,998
	Program		30,549,711
<b>Total</b>		<b>\$</b>	<b>39,150,984</b>



## Program Expenses

	Research	\$	18,293,927
	TREAT Asia		5,051,148
	GMT Initiative		921,895
	Public Policy		2,140,923
	Public Information		4,141,818
<b>Total</b>		<b>\$</b>	<b>30,549,711</b>



## BOARD OF TRUSTEES

Fiscal year 2018

Chairman of the Board

[William H. Roedy](#)  
London, UK

Vice Chairman

[Cindy Rachofsky](#)  
Philanthropist  
Dallas, Texas

Treasurer

[Michael Klingensmith](#)  
Publisher and CEO  
Star Tribune Media Company  
Minneapolis, MN

Secretary

[Arlen H. Andelson](#)  
Senior Partner (ret.)  
Andelson & Andelson  
Los Angeles, CA

### TRUSTEES

[Harry Belafonte](#)

President  
Belafonte Enterprises, Inc.  
New York, NY

[Zev Braun](#)

President and CEO  
Braun Entertainment Group, Inc.  
Beverly Hills, CA

[Jonathan S. Canno](#)

New York, NY

[Aileen Getty](#)

Founder and President  
The Aileen Getty Foundation  
Reno, NV

[Michele V. McNeill, Pharm.D.](#)

Chairman  
McNeill Family Foundation  
Sarasota, FL

[Edward L. Milstein](#)

Co-Chairman, Milford Management  
Co-Chairman, Emigrant Savings Bank  
Partner, Milstein Properties  
New York, NY

[Raymond F. Schinazi, Ph.D., D.Sc.](#)

Frances Winship Walters Professor of Pediatrics  
Director, Laboratory of Biochemical Pharmacology  
Emory University  
Decatur, GA

[Alan D. Schwartz](#)

Executive Chairman  
Guggenheim Partners, LLC  
New York, NY

[Mario Stevenson, Ph.D.](#)

Professor of Medicine  
Chief, Division of Infectious Diseases  
University of Miami  
Leonard M. Miller School of Medicine  
Miami, FL

### TRUSTEE EMERITUS

[Arthur J. Ammann, M.D.](#)

President, Global Strategies for HIV Prevention  
Clinical Professor of Pediatrics  
University of California, San Francisco  
San Francisco, CA

### IN MEMORIAM

[Mathilde Krim, Ph.D.](#)

Founding Chairman

[Dame Elizabeth Taylor](#)

Founding International Chairman

[Sheldon W. Andelson, Esq.](#)

[Arnold W. Klein, M.D.](#)

[Mrs. Albert D. Lasker](#)

[Jonathan M. Mann, M.D., M.P.H.](#)

[Maxine Mesinger](#)

[Pauline Phillips](#)

[Natasha Richardson](#)

[Allan Rosenfield, M.D.](#)

[Peter Scott, Esq.](#)

[Tom Stoddard](#)

[Joel D. Weisman, D.O.](#)

### SPECIAL APPOINTMENTS

Global Campaign Chair

[Sharon Stone](#)

Global Fundraising Chairman

[Milutin Gatsby](#)

### amfAR AMBASSADORS

[Cheyenne Jackson](#)

[Janet Jackson](#)

[Milla Jovovich](#)

[Liza Minnelli](#)

[Michelle Yeoh](#)

### COMMITTEES OF THE BOARD OF TRUSTEES

#### Executive

William H. Roedy, Chair

Cindy Rachofsky

Michael J. Klingensmith

Arlen H. Andelson

Alan D. Schwartz

#### Audit

Alan D. Schwartz, Chair

Arlen H. Andelson

Edward L. Milstein

#### Board Development

Cindy Rachofsky, Chair

Arlen Andelson

Aileen Getty

Edward L. Milstein

William H. Roedy

Alan D. Schwartz

#### Communications/Social Media/Marketing

William H. Roedy, Chair

Harry Belafonte

Aileen Getty

#### Compensation and Organizational Development

Michael J. Klingensmith, Chair

Arlen Andelson

Mario Stevenson, Ph.D.

#### Finance & Budget

Michael J. Klingensmith, Chair

Edward L. Milstein

Mario Stevenson, Ph.D.

#### Fund Development

Cindy Rachofsky, Chair

Jonathan S. Canno

Aileen Getty

Edward L. Milstein

Raymond F. Schinazi, Ph.D., D.Sc.

#### Investment

Michael J. Klingensmith, Chair

R. Martin Chavez, Ph.D.

T. Ryan Greenawalt

Edward L. Milstein

Vincent A. Roberti

John C. Simons

## SCIENTIFIC ADVISORY COMMITTEE

\*Adjunct Member

[Jintanat Ananworanich, M.D., Ph.D. \(Chair\)](#)

Associate Director for Therapeutics Research  
U.S. Military HIV Research Program

[Patrick Arbuthnot, Ph.D.\\*](#)

Director

Antiviral Gene Therapy Research Unit

University of the Witwatersrand

[Alberto Bosque, Ph.D.\\*](#)

Assistant Professor

Department of Microbiology, Immunology, and

Tropical Medicine

The George Washington University

[Jason Brenchley, Ph.D.\\*](#)

Senior Investigator

Immunopathogenesis Section

National Institute of Allergy and Infectious

Diseases

National Institutes of Health

[Wendy Burgers, M.Sc., Ph.D.\\*](#)

Senior Researcher

Division of Medical Virology

Institute of Infectious Diseases and Molecular

Medicine

University of Cape Town

[Dennis R. Burton, Ph.D.](#)

Professor

Department of Immunology

The Scripps Research Institute

[Benjamin Burwitz, Ph.D.\\*](#)

Research Assistant Professor

Vaccine and Gene Therapy Institute

Oregon Health and Science University

[Salvatore T. Butera, D.V.M., Ph.D.](#)

Chief Science Officer

Scripps CHAVI-ID

The Scripps Research Institute

**Edward Campbell, Ph.D.**

Assistant Professor  
Department of Microbiology and Immunology  
School of Medicine  
Loyola University at Chicago

**Alex Carballo-Diequez, Ph.D.**

Co-Director and Senior Research Scientist  
HIV Center for Clinical and Behavioral Studies  
New York State Psychiatric Institute  
Columbia University

**Ann Chahroudi, M.D., Ph.D.\***

Associate Director, Clinical Affairs  
School of Medicine  
Emory University

**David B. Clifford, M.D.**

Professor  
Department of Neurology  
Washington University School of Medicine

**Leslie Cockerham, M.D.\***

Assistant Professor of Medicine  
Division of Infectious Diseases  
Medical College of Wisconsin

**C. Budd Colby, Ph.D.**

Principal  
Colby Biomedical Ventures

**Grant Colfax, M.D.**

Director  
Marin Health and Human Services  
San Rafael, California

**Deborah Jean Cotton, M.D., M.P.H.**

Professor of Medicine  
Boston University School of Medicine

**Bryan R. Cullen, Ph.D., D.Sc.**

James B. Duke Professor  
Department of Molecular Genetics and  
Microbiology  
Director, Duke University Center for Virology  
Duke University Medical Center

**Susanna Cunningham-Rundles, Ph.D.**

Professor Emerita of Research Immunology  
Department of Pediatrics  
Weill Cornell Medical College

**Richard Thomas D'Aquila, M.D.**

The Howard Taylor Ricketts Professor of Medicine  
Division of Infectious Diseases  
Director, Northwestern HIV Translational  
Research Center  
Feinberg School of Medicine  
Northwestern University

**Bruno De Geest, Ph.D.**

Chemical Engineer  
Laboratory of Pharmaceutical Technology  
Ghent University Hospital

**Sherry Deren, Ph.D.**

Co-Director  
Center for Drug Use and HIV Research  
New York University College of Nursing

**Roger Detels, M.D., M.S.**

Professor of Epidemiology  
School of Public Health  
University of California, Los Angeles

**Felipe Diaz-Griffero, Ph.D.\***

Professor  
Elsie Wachtel Faculty Scholar  
Department of Microbiology & Immunology  
Albert Einstein College of Medicine

**Carl W. Dieffenbach, Ph.D.**

Director  
Division of AIDS (DAIDS)  
National Institute of Allergy and Infectious  
Diseases  
National Institutes of Health

**Ivan D'Orso, Ph.D.\***

Associate Professor  
Department of Microbiology  
University of Texas Southwestern

**Daniel C. Douek, M.D., Ph.D.**

Chief, Human Immunology Section  
Vaccine Research Center  
National Institute of Allergy and Infectious  
Diseases  
National Institutes of Health

**D. Peter Drotman, M.D., M.P.H.**

Editor-in-Chief  
Emerging Infectious Diseases  
Centers for Disease Control and Prevention

**Anke A. Ehrhardt, Ph.D.**

Director  
Division of Gender, Sexuality, & Health  
Program for the Study of LGBT Health  
NYS Psychiatric Institute/Columbia University

**Susan Engelbrecht, Ph.D.\***

Medical Scientist  
Division of Medical Virology  
Faculty of Medicine & Health Sciences  
Stellenbosch University and NHLS

**Lucie Etienne, Ph.D.\***

Assistant Professor  
Centre International de Recherche en Infectiologie  
Institut National de la Santé et de la Recherche  
Médicale, INSERM

**Homayoon Farzadegan, Ph.D.**

Professor  
Department of Epidemiology  
Johns Hopkins Bloomberg School of Public Health

**Daniela Fera, Ph.D.\***

Assistant Professor of Chemistry and Biochemistry  
Swarthmore College

**Dianne M. Finkelstein, Ph.D.**

Professor of Biostatistics  
Harvard T.H. Chan School of Public Health  
Director of Biostatistics  
Massachusetts General Hospital Cancer Center

**Andrés Finzi, Ph.D.\***

Associate Professor  
Department of Microbiology and Immunology  
Université de Montréal, Centre de Recherche du  
CHUM

**Gerald Herbert Friedland, M.D.**

Professor and Director  
AIDS Care Program  
Department of Internal Medicine  
Yale School of Medicine

**Howard E. Gendelman, M.D.**

Professor and Chair, Department of Pharmacology  
and Experimental Neuroscience  
Margaret R. Larson Professor of Internal Medicine  
and Infectious Diseases  
Director, Center for Neurodegenerative Disorders  
University of Nebraska Medical Center

**Catherine Godfrey, M.D.\***

Division of AIDS  
National Institute of Allergy and Infectious  
Diseases  
National Institutes of Health

**Warner Greene, M.D., Ph.D.\***

Professor  
Director and Senior Investigator  
Center for HIV Cure Research  
Gladstone Institutes

**Huldrych Günthard, M.D.\***

Professor of Infectious Diseases  
Senior Staff Physician/Deputy Director  
Department of Infectious Diseases and Hospital  
Epidemiology  
University Hospital of Zurich

**Nancy L. Haigwood, Ph.D.**

Director and Senior Scientist  
Division of Pathobiology and Immunology  
Oregon National Primate Research Center  
Oregon Health and Science University

**Andrew Henderson, Ph.D.\***

Associate Professor  
School of Medicine  
Boston University

**Joshua Herbeck\***

Assistant Professor  
Department of Global Health  
University of Washington

**Charles H. Hinkin, Ph.D.**

Professor  
Department of Psychiatry and Biobehavioral  
Sciences  
David Geffen School of Medicine  
University of California, Los Angeles

**David Ho, M.D.**

Scientific Director, Chief Executive Officer  
Aaron Diamond AIDS Research Center

**Ya-Chi Ho, M.D., Ph.D.\***

Assistant Professor of Microbial Pathogenesis and  
Medicine  
Yale University

**Thomas J. Hope, Ph.D.**

Professor  
Department of Cell and Molecular Biology  
Feinberg School of Medicine  
Northwestern University

**Bonnie Howell, Ph.D.\***

Executive Director, Infectious Disease and  
Vaccines  
Merck & Co., Inc.

**Shiu-Lok Hu, Ph.D.**

Professor  
School of Pharmacy  
University of Washington

**Nolwenn Jouvenet, Ph.D.\***

Group Leader  
Viral Genomics and Vaccination  
Department of Virology  
Institut Pasteur

**Jonathan Karn, Ph.D.\***

Director  
Center for AIDS Research  
Case Western Reserve University

**Elly Katabira, M.D., F.R.C.P.\***

Professor of Medicine  
Department of Medicine  
Makerere University

**Vineet KewalRamani, Ph.D.**

Chief, Model Development Section  
HIV Drug Resistance Program  
National Cancer Institute  
National Institutes of Health

**Scott Kitchen, Ph.D.**

Assistant Professor of Medicine  
Division of Hematology and Oncology  
David Geffen School of Medicine  
University of California, Los Angeles

**Neeltje Kootstra, Ph.D.\***

Principal Investigator  
Amsterdam UMC (location AMC)  
University of Amsterdam

**Richard Kornbluth, M.D., Ph.D.**

President and Chief Scientific Officer  
Multimeric Biotherapeutics, Inc.

**Richard A. Koup, M.D.**

Deputy Director, Vaccine Research Center  
Chief, Immunology Laboratory  
National Institute of Allergy and Infectious Diseases  
National Institutes of Health

**Daniel Kuritzkes, M.D.\***

Harriet Ryan Albee Professor of Medicine  
Department of Medicine  
Brigham and Women's Hospital

**Nathaniel R. Landau, Ph.D.**

Professor  
Department of Microbiology  
New York University School of Medicine

**Alan L. Landay, Ph.D.**

Professor and Chairman  
Department of Immunology and Microbiology  
Rush-Presbyterian-St. Luke's Medical Center

**Michael Lederman, M.D.**

Scott R. Inkley Professor of Medicine  
Associate Director, Center for AIDS Research  
Case Western Reserve University

**Tun-Hou Lee, D.Sc.**

Professor of Virology, Emeritus  
Department of Immunology and Infectious Diseases  
Harvard School of Public Health

**Dara Lehman, Ph.D.\***

Affiliate Assistant Professor  
Department of Global Health  
Fred Hutchinson Cancer Research Center

**Michael J. Leibowitz, M.D., Ph.D.**

Professor, Medical Microbiology and Immunology  
University of California, Davis

**Robert J. Levine, M.D.**

Professor of Medicine  
Center for Interdisciplinary Research on AIDS  
Yale University

**Judy Lieberman, M.D., Ph.D.**

Senior Investigator  
Immune Disease Institute  
Professor of Pediatrics  
Harvard Medical School

**H. Kim Lyerly, M.D.**

Professor in Surgery, Immunology, Pathology  
George Barth Geller Chair of Cancer Research  
Director of the Center of Applied Therapeutics  
Duke Cancer Institute  
Duke University Medical Center

**Frank Maldarelli, M.D., Ph.D.**

Investigator  
HIV DRP Host-Virus Interaction Branch  
National Cancer Institute  
National Institutes of Health

**David M. Margolis, M.D.**

Professor of Medicine, Microbiology and Immunology, and Epidemiology  
School of Medicine  
University of North Carolina at Chapel Hill

**Martin H. Markowitz, M.D.**

Professor and Clinical Director  
Aaron Diamond AIDS Research Center

**Kenneth Hugh Mayer, M.D.**

Infectious Disease Attending & Director of HIV Prevention Research  
Beth Israel Deaconess Medical Center  
Professor of Medicine  
Harvard Medical School  
Medical Research Director, Co-Chair  
The Fenway Institute/Fenway Health

**Joseph M. McCune, M.D., Ph.D.**

Professor of Medicine  
Department of Medicine  
University of California, San Francisco

**Donna Mildvan, M.D.**

Chief, Division of Infectious Diseases  
Department of Medicine  
Beth Israel Medical Center

**Paula Munderi, M.D., F.R.C.P.\***

Head of the HIV Care Research Programme  
Medical Research Council Research Unit on AIDS  
Uganda Virus Research Institute

**Lishomwa Ndhlovu, M.D., Ph.D.\***

Associate Professor  
Department of Tropical Medicine, Medical Microbiology and Pharmacology  
John A. Burns School of Medicine  
University of Hawaii, Manoa

**Thumbi Ndung'u, Ph.D.\***

Investigator and Max Planck Institute for Infection Biology Research Group Leader  
KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH)

**Jay A. Nelson, Ph.D.**

Professor and Director  
Vaccine and Gene Therapy Institute  
Oregon Health and Science University

**David O'Connor, Ph.D.\***

Professor  
Pathology and Laboratory Medicine  
University of Wisconsin-Madison

**Nancy Padian, Ph.D., M.P.H.**

Adjunct Professor of Epidemiology  
School of Public Health  
University of California, Berkeley

**Savita Pahwa, M.D.**

Professor of Microbiology and Immunology  
Professor in Pediatrics and Medicine  
Director of the Miami Center for AIDS Research  
University of Miami Leonard M. Miller School of Medicine

**Tristram G. Parslow, M.D., Ph.D.**

William Patterson Timmie Professor and Chair  
Department of Pathology and Laboratory Medicine  
Emory University School of Medicine

**Matija Peterlin, M.D.**

Professor of Medicine, Microbiology and Immunology  
Department of Medicine  
University of California, San Francisco

**Matthew Porteus, M.D., Ph.D.\***

Associate Professor  
Pediatrics - Stem Cell Transplantation  
Stanford University

**Lynn Pulliam, Ph.D.**

Professor  
Department of Laboratory Medicine and Medicine  
University of California, San Francisco  
Veterans Affairs Medical Center

**Lee Ratner, M.D., Ph.D.**

Professor  
Department of Medicine  
Washington University School of Medicine

**Roger Keith Reeves, Ph.D.\***

Assistant Professor in Medicine  
Center for Virology and Vaccine Research  
Beth Israel Deaconess Medical Center

**Andrew Rice, Ph.D.**

Professor  
Department of Molecular Virology and Microbiology  
Baylor College of Medicine

**Melissa Robbiani, Ph.D.**

Senior Scientist and Director of Biomedical HIV Research  
Center for Biomedical Research  
Population Council

**Harriet Robinson, Ph.D.\***

Chief Scientific Officer Emeritus  
GeoVax

**Fabio Romero, Ph.D.\***

Assistant Professor  
Department of Medicine  
Institute of Human Virology  
University of Maryland

**Ruth M. Ruprecht, M.D., Ph.D.**

Scientist, Department of Virology and Immunology  
Southwest National Primate Research Center  
Director, Texas Biomed AIDS Research Program  
Texas Biomedical Research Institute

**Timothy Schacker, M.D.\***

Professor of Medicine  
Division of Infectious Disease and International Medicine  
Department of Medicine  
University of Minnesota

**Frederick A. Schmitt, Ph.D.**

Professor  
Departments of Neurology, Psychiatry, and Psychology and Behavioral Science  
Sanders Brown Center on Aging  
University of Kentucky



**Gerald Schochetman, Ph.D.**

Senior Director  
Diagnostics Research  
Abbott Laboratories

**Amit Sharma, Ph.D.\***

Assistant Professor  
Department of Veterinary Biosciences  
Department of Microbial Infection and Immunity  
The Ohio State University

**Gail Skowron, M.D.**

Professor of Medicine  
Boston University School of Medicine

**Davey Smith, M.D.\***

Professor  
Department of Medicine  
University of California, San Diego

**Celsa Spina, Ph.D.\***

Associate Professor  
Department of Pathology  
University of California, San Diego

**Adam Spivak, M.D.\***

Assistant Professor  
Division of Infectious Diseases  
University of Utah

**Leonidas Stamatatos, Ph.D.**

Member  
Fred Hutchinson Cancer Research Center  
Vaccine and Infectious Disease Division  
Immunology and Vaccine Development Program  
Seattle, WA

**Mario Stevenson, Ph.D.**

Professor of Medicine  
Chief, Division of Infectious Diseases  
University of Miami Leonard M. Miller School of  
Medicine

**Rob Striker, M.D., Ph.D.\***

Associate Professor  
Department of Infectious Diseases  
University of Wisconsin-Madison

**Koen van Besien, M.D.\***

Professor  
Bone Marrow and Stem Cell Transplant Program  
Richard T. Silver, M.D. Myeloproliferative  
Neoplasms (MPN) Center  
Weill Cornell Medical College

**Gert van Zyl, M.B.Ch.B. (Pret), M.Med. (SU),  
F.C.Path. (SA), Ph.D. (SU)\***

Associate Professor  
Division of Medical Virology  
Department of Pathology  
Stellenbosch University, Faculty of Medicine &  
Health Sciences; and National Health Laboratory  
Services, Tygerberg

**Linus Vandekerckhove, M.D., Ph.D.\***

Professor  
Department of General Internal Medicine  
Ghent University Hospital

**Barbara Visscher, M.D., Dr.P.H.**

Professor of Epidemiology  
University of California, Los Angeles

**David Vlahov, Ph.D., R.N.**

Professor of Nursing,  
Epidemiology, and Biostatistics  
University of California, San Francisco

**David J. Volsky, Ph.D.**

Professor of Medicine and Pathology  
Icahn School of Medicine at Mount Sinai  
Director of Molecular Virology Laboratory  
Department of Medicine  
Mount Sinai St. Luke's and Roosevelt Hospitals

**Steven S. Witkin, Ph.D.**

Professor of Immunology  
Department of Obstetrics and Gynecology  
Weill Cornell Medical College

**Peter R. Wolfe, M.D.**

Associate Clinical Professor  
David Geffen School of Medicine  
University of California, Los Angeles  
Sub-Investigator  
Ruane Clinical Research

**Richard T. Wyatt, Ph.D.**

Professor of Immunology  
IAVI Center for Neutralizing Antibodies  
The Scripps Research Institute

**Alexander Zelikin, Ph.D.\***

Associate Professor  
Department of Chemistry  
Aarhus University

**Katherine Luzuriaga, M.D.**

Professor, Molecular Medicine, Pediatrics and  
Medicine  
University of Massachusetts Medical School  
Worcester, MA

**Kenneth H. Mayer, M.D.**

Infectious Disease Attending and  
Director of HIV Prevention Research  
Beth Israel Deaconess Medical Center

Professor of Medicine  
Harvard Medical School

Medical Research Director and Co-Chair  
The Fenway Institute/Fenway Health

**Jeffrey L. Sturchio, Ph.D.**

President and Chief Executive Officer  
Rabin Martin, NYC

Visiting Scholar  
The Institute for Applied Economics, Global Health  
and the Study of Business Enterprise  
Johns Hopkins University

Member  
The Council on Foreign Relations

**Phill Wilson**

Chief Executive Officer and President  
The Black AIDS Institute  
Los Angeles, CA

## PROGRAM ADVISORY COUNCIL

**Mervyn F. Silverman, M.D., M.P.H. (Chairman)**

President  
Mervyn F. Silverman Associates  
Crockett, CA

**Jintanat Ananwornich, M.D., Ph.D.**

Associate Director for Therapeutics Research  
U.S. Military HIV Research Program  
Bethesda, MD

**Judith D. Auerbach, Ph.D.**

Science and Policy Consultant, and Professor  
School of Medicine  
University of California, San Francisco

**David Bloom, Ph.D.**

Clarence James Gamble Professor of Economics  
and Demography  
Department of Global Health and Population  
Harvard T.H. Chan School of Public Health  
Boston, MA

**Tim Brown, Ph.D.**

Senior Fellow  
The East-West Center  
Honolulu, HI

**Daniel Douek, M.D., Ph.D.**

Chief, Human Immunology Section  
Vaccine Research Center  
National Institute of Allergy and Infectious  
Diseases  
National Institutes of Health

**Daria J. Hazuda, Ph.D.**

Vice President, Scientific Affairs for Infectious  
Disease  
Merck & Company, Inc.  
West Point, PA

## MANAGEMENT GROUP

**Kevin Robert Frost**

Chief Executive Officer

**Anthony Ancona**

Vice President and Director, Human Resources

**Susan J. Blumenthal, M.D., M.P.A.**

Senior Policy and Medical Advisor

**Bradley Jensen**

Chief Financial Officer

**Rowena Johnston, Ph.D.**

Vice President and Director, Research

**Jeffrey Laurence, M.D.**

Senior Scientific Consultant for Programs

**Gregorio Millett, M.P.H.**

Vice President and Director, Public Policy

**Eric Muscatell**

Vice President, Development

**AnnMari Shannahan**

Vice President, Public Information

**Annette Sohn, M.D.**

Vice President and Director, TREAT Asia



**amfAR, The Foundation for AIDS Research**

**NEW YORK**

120 Wall Street, 13th Floor  
New York, NY 10005-3908  
(212) 806-1600 (tel)  
(212) 806-1601 (fax)

**WASHINGTON, D.C.**

1100 Vermont Avenue, NW  
Suite 600  
Washington, DC 20005  
(202) 331-8600 (tel)  
(202) 331-8606 (fax)

**BANGKOK, THAILAND**

TREAT Asia  
Exchange Tower  
388 Sukhumvit Road, Suite 2104  
Klongtoey, Bangkok 10110  
Thailand  
+66 (0)2 663 7561 (tel)  
+66 (0)2 663 7562 (fax)

**[www.amfar.org](http://www.amfar.org)**



[bbb.org/charity](http://bbb.org/charity)

amfAR meets the BBB  
Wise Giving Alliance's  
Standards for Charity  
Accountability.



★★★★  
**CHARITY NAVIGATOR**  
Four Star Charity



**COMMUNITY**  
HEALTH CHARITIES